US6225289B1
(en)
|
1998-12-10 |
2001-05-01 |
Genvec, Inc. |
Methods and compositions for preserving adenoviral vectors
|
ES2228454T3
(es)
*
|
1999-02-26 |
2005-04-16 |
Chiron S.R.L. |
Mejora de la actividad bacteriana de antigenos de neisseria con oligonucleotidos que contienen motivos cg.
|
US6558670B1
(en)
|
1999-04-19 |
2003-05-06 |
Smithkline Beechman Biologicals S.A. |
Vaccine adjuvants
|
CZ303515B6
(cs)
|
1999-04-19 |
2012-11-07 |
Smithkline Beecham Biologicals S. A. |
Adjuvantní prostredek
|
JP4974414B2
(ja)
*
|
1999-05-13 |
2012-07-11 |
ワイス・ホールディングズ・コーポレイション |
アジュバント混合製剤
|
GB9921146D0
(en)
*
|
1999-09-07 |
1999-11-10 |
Smithkline Beecham Biolog |
Novel composition
|
WO2001030847A1
(fr)
|
1999-10-22 |
2001-05-03 |
Aventis Pasteur Limited |
Molecule gp100 modifiee et ses applications
|
AU5810201A
(en)
|
2000-05-10 |
2001-11-20 |
Aventis Pasteur |
Immunogenic polypeptides encoded by mage minigenes and uses thereof
|
PT1889630E
(pt)
|
2000-10-18 |
2012-02-29 |
Glaxosmithkline Biolog Sa |
Vacinas compreendendo o antigénio mage ligado a um fragmento da proteína d
|
MY134424A
(en)
*
|
2001-05-30 |
2007-12-31 |
Saechsisches Serumwerk |
Stable influenza virus preparations with low or no amount of thiomersal
|
US20040241094A1
(en)
*
|
2001-09-13 |
2004-12-02 |
Hesson Chung |
Oily paclitaxel composition and formulation for chemoembolization and preparation method thereof
|
WO2004012751A1
(fr)
*
|
2002-08-02 |
2004-02-12 |
Sumitomo Pharmaceuticals Company, Limited |
Preparation d'un compose bacterien de squelette de paroi cellulaire
|
PL376792A1
(pl)
|
2002-10-23 |
2006-01-09 |
Glaxosmithkline Biologicals S.A. |
Sposoby szczepienia przeciwko malarii
|
GB0411411D0
(en)
*
|
2004-05-21 |
2004-06-23 |
Glaxosmithkline Biolog Sa |
Vaccines
|
CA2565500A1
(fr)
|
2004-05-28 |
2005-12-15 |
Glaxosmithkline Biologicals S.A. |
Compositions de vaccin comprenant des virosomes et un adjuvant a base de saponine
|
GB0417494D0
(en)
|
2004-08-05 |
2004-09-08 |
Glaxosmithkline Biolog Sa |
Vaccine
|
PT1861120T
(pt)
|
2005-03-23 |
2016-08-18 |
Glaxosmithkline Biologicals Sa |
Utilização de um vírus influenza e de um adjuvante de emulsão óleo-em-água para induzir células t cd4 e/ou melhorar a resposta de células b de memória
|
GB0513421D0
(en)
|
2005-06-30 |
2005-08-03 |
Glaxosmithkline Biolog Sa |
Vaccines
|
US11707520B2
(en)
|
2005-11-03 |
2023-07-25 |
Seqirus UK Limited |
Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
|
ES2420829T3
(es)
*
|
2005-11-04 |
2013-08-27 |
Novartis Vaccines And Diagnostics S.R.L. |
Vacunas adyuvantadas con antígeno de no virión preparadas a partir de virus de la gripe cultivados en cultivo celular
|
GB0522765D0
(en)
|
2005-11-08 |
2005-12-14 |
Chiron Srl |
Combination vaccine manufacture
|
AR058707A1
(es)
|
2005-12-22 |
2008-02-20 |
Glaxosmithkline Biolog Sa |
Vacuna, procedimiento para fabricarla y su uso
|
GB0607088D0
(en)
|
2006-04-07 |
2006-05-17 |
Glaxosmithkline Biolog Sa |
Vaccine
|
JP2009531387A
(ja)
|
2006-03-30 |
2009-09-03 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
免疫原性組成物
|
US9839685B2
(en)
|
2006-04-13 |
2017-12-12 |
The Regents Of The University Of Michigan |
Methods of inducing human immunodeficiency virus-specific immune responses in a host comprising nasally administering compositions comprising a naonemulsion and recombinant GP120 immunogen
|
US10138279B2
(en)
|
2006-04-13 |
2018-11-27 |
Regents Of The University Of Michigan |
Compositions and methods for Bacillus anthracis vaccination
|
MX2009000660A
(es)
|
2006-07-17 |
2009-04-08 |
Glaxosmithkline Biolog Sa |
Vacuna de influenza.
|
AU2007276219B2
(en)
|
2006-07-18 |
2013-10-03 |
Glaxosmithkline Biologicals S.A. |
Vaccines for malaria
|
US8323664B2
(en)
|
2006-07-25 |
2012-12-04 |
The Secretary Of State For Defence |
Live vaccine strains of Francisella
|
PL2486938T3
(pl)
|
2006-09-26 |
2018-08-31 |
Infectious Disease Research Institute |
Kompozycja szczepionki zawierająca syntetyczny adiuwant
|
US20090181078A1
(en)
|
2006-09-26 |
2009-07-16 |
Infectious Disease Research Institute |
Vaccine composition containing synthetic adjuvant
|
KR101192127B1
(ko)
|
2006-11-03 |
2012-10-17 |
쉐링-프라우 리미티드 |
개 라임병 백신
|
EP2137210B1
(fr)
|
2007-03-02 |
2016-10-19 |
GlaxoSmithKline Biologicals SA |
Nouveau procédé et nouvelles compositions
|
PE20090146A1
(es)
|
2007-04-20 |
2009-03-23 |
Glaxosmithkline Biolog Sa |
Composicion inmunogenica contra el virus influenza
|
EA200901578A1
(ru)
|
2007-06-26 |
2010-08-30 |
Глаксосмитклайн Байолоджикалс С.А. |
Вакцина, содержащая конъюгаты капсульных полисахаридов streptococcus pneumoniae
|
WO2009021931A1
(fr)
|
2007-08-13 |
2009-02-19 |
Glaxosmithkline Biologicals S.A. |
Vaccins
|
EP3118213A1
(fr)
|
2007-12-19 |
2017-01-18 |
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. |
Formes solubles de virus hendra et nipah glycoprotéine f et leurs utilisations
|
US9415006B2
(en)
|
2008-05-23 |
2016-08-16 |
The Regents Of The University Of Michigan |
Immunogenic compositions comprising nanoemulsion and hepatitis B virus immunogen and methods of using the same
|
GB0815872D0
(en)
|
2008-09-01 |
2008-10-08 |
Pasteur Institut |
Novel method and compositions
|
US20100092526A1
(en)
|
2008-09-26 |
2010-04-15 |
Nanobio Corporation |
Nanoemulsion therapeutic compositions and methods of using the same
|
GB0901411D0
(en)
|
2009-01-29 |
2009-03-11 |
Secr Defence |
Treatment
|
GB0901423D0
(en)
|
2009-01-29 |
2009-03-11 |
Secr Defence |
Treatment
|
CN102307590A
(zh)
|
2009-02-10 |
2012-01-04 |
诺华有限公司 |
具有减少量的角鲨烯的流感疫苗
|
GB0906234D0
(en)
|
2009-04-14 |
2009-05-20 |
Secr Defence |
Vaccine
|
US8668911B2
(en)
|
2009-05-14 |
2014-03-11 |
The Regents Of The University Of Michigan |
Streptococcus vaccine compositions and methods of using the same
|
ES2606563T3
(es)
|
2009-06-05 |
2017-03-24 |
Infectious Disease Research Institute |
Adyuvantes lipídicos de glucopiranosilo sintéticos y composiciones de vacuna que contienen los mismos
|
ES2566646T3
(es)
|
2009-06-16 |
2016-04-14 |
The Regents Of The University Of Michigan |
Vacunas en nanoemulsión
|
GB0913681D0
(en)
|
2009-08-05 |
2009-09-16 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
GB0913680D0
(en)
|
2009-08-05 |
2009-09-16 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
GB0919117D0
(en)
|
2009-10-30 |
2009-12-16 |
Glaxosmithkline Biolog Sa |
Process
|
DE102009056883B4
(de)
*
|
2009-12-03 |
2012-08-16 |
Novartis Ag |
Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
|
EP2353609A1
(fr)
|
2010-02-04 |
2011-08-10 |
Sanofi Pasteur |
Compositions et procédés d'immunisation
|
GB201003920D0
(en)
|
2010-03-09 |
2010-04-21 |
Glaxosmithkline Biolog Sa |
Method of treatment
|
WO2011117408A1
(fr)
|
2010-03-26 |
2011-09-29 |
Glaxosmithkline Biologicals S.A. |
Vaccin contre le hiv
|
US8658603B2
(en)
|
2010-06-16 |
2014-02-25 |
The Regents Of The University Of Michigan |
Compositions and methods for inducing an immune response
|
BR112013004582A2
(pt)
|
2010-09-27 |
2016-09-06 |
Crucell Holland Bv |
método para induzir uma resposta imune em um sujeito contra um antígeno de um parasita que causa a malária
|
EA201390452A1
(ru)
|
2010-09-27 |
2013-11-29 |
Глаксосмитклайн Байолоджикалс С.А. |
Вакцина
|
CA2819416C
(fr)
|
2010-12-02 |
2019-04-30 |
Bionor Immuno As |
Conception d'echafaudage peptidique
|
GB201022007D0
(en)
|
2010-12-24 |
2011-02-02 |
Imp Innovations Ltd |
DNA-sensor
|
US9493514B2
(en)
|
2011-01-06 |
2016-11-15 |
Bionor Immuno As |
Dimeric scaffold proteins comprising HIV-1 GP120 and GP41 epitopes
|
EP2694099B1
(fr)
|
2011-04-08 |
2019-10-16 |
Immune Design Corp. |
Compositions immunogènes et leurs procédés d'utilisation pour induire des réponses immunitaires humorales et cellulaires
|
CN103958544B
(zh)
|
2011-09-16 |
2018-04-24 |
Ucb医药有限公司 |
针对艰难梭菌的主要外毒素TcdA和TcdB的中和抗体
|
US20130122038A1
(en)
|
2011-11-14 |
2013-05-16 |
The United States Of America As Represented By The Secretary Of The Department |
Heterologous prime-boost immunization using measles virus-based vaccines
|
EP2788477A2
(fr)
|
2011-12-07 |
2014-10-15 |
Institut Pasteur |
Identification d'un virus porcin de type paréchovirus et applications
|
LT2811981T
(lt)
|
2012-02-07 |
2019-06-10 |
Infectious Disease Research Institute |
Pagerintos adjuvanto kompozicijos, apimančios tlr4 agonistus, ir jų panaudojimo būdai
|
PL2850431T3
(pl)
|
2012-05-16 |
2018-09-28 |
Immune Design Corp. |
Szczepionki przeciwko HSV-2
|
MX2014014683A
(es)
|
2012-06-06 |
2015-02-24 |
Bionor Immuno As |
Peptidos derivados de proteinas virales para usarse como inmunogenos y reactivos de dosificacion.
|
US20150265695A1
(en)
|
2012-07-24 |
2015-09-24 |
Sanofi Pasteur |
Vaccine compositions for prevention against dengue virus infection
|
SG11201500412TA
(en)
|
2012-07-24 |
2015-02-27 |
Sanofi Pasteur |
Vaccine compositions
|
DK2912186T3
(da)
|
2012-10-24 |
2021-02-22 |
Platelet Targeted Therapeutics Llc |
Behandling rettet mod blodplader
|
BR112015012515B1
(pt)
|
2012-11-30 |
2023-04-11 |
Sanofi Pasteur |
Uso de antígenos, construções de ácido nucleico ou vetores virais capazes de expressar uma partícula do tipo vírus (vlp) da dengue e de uma vacina contra sarampo, uma vacina contra caxumba e uma vacina contra rubéola
|
SG11201508092YA
(en)
|
2013-04-18 |
2015-10-29 |
Immune Design Corp |
Gla monotherapy for use in cancer treatment
|
US9463198B2
(en)
|
2013-06-04 |
2016-10-11 |
Infectious Disease Research Institute |
Compositions and methods for reducing or preventing metastasis
|
EP3063171B1
(fr)
|
2013-11-01 |
2019-07-24 |
University Of Oslo |
Variants d'albumine et utilisations de ceux-ci
|
WO2015070207A2
(fr)
|
2013-11-11 |
2015-05-14 |
The Government Of The United States, As Represented By The Secretary Of The Army |
Épitopes ama-1, anticorps, compositions et leurs procédés de production et d'utilisation
|
US9993541B2
(en)
|
2013-11-13 |
2018-06-12 |
University Of Oslo |
Outer membrane vesicles and uses thereof
|
WO2015071763A2
(fr)
|
2013-11-15 |
2015-05-21 |
Oslo Universitetssykehus Hf |
Epitopes peptidiques de lymphocytes t cytotoxiques et lymphocytes t specifiques a l'antigene, procede pour leur decouverte, et leurs utilisations
|
WO2015077434A2
(fr)
|
2013-11-20 |
2015-05-28 |
La Jolla Institute For Allergy And Immunology |
Immunogènes contre plusieurs pollens et procédés et utilisations pour moduler la réponse immunitaire
|
WO2015077442A2
(fr)
|
2013-11-20 |
2015-05-28 |
La Jolla Institute For Allergy And Immunology |
Immunogènes de pollen de graminée ainsi que procédés et utilisations pour la modulation de la réponse immunitaire
|
WO2015092710A1
(fr)
|
2013-12-19 |
2015-06-25 |
Glaxosmithkline Biologicals, S.A. |
Administration simultanée controlatérale de vaccins
|
EA201691348A1
(ru)
|
2013-12-31 |
2016-11-30 |
Инфекшес Дизиз Рисерч Инститьют |
Однофлаконные вакцинные составы
|
WO2015112485A1
(fr)
|
2014-01-21 |
2015-07-30 |
Immune Design Corp. |
Compositions à utiliser pour le traitement d'états allergiques
|
WO2015131053A1
(fr)
|
2014-02-28 |
2015-09-03 |
Alk-Abelló A/S |
Polypeptides dérivés de phl p, procédés et utilisations de ces derniers pour moduler une réponse immunitaire
|
KR101696514B1
(ko)
*
|
2014-08-18 |
2017-01-24 |
서울대학교산학협력단 |
신규한 온도 민감성 마이코박테리아 균주 및 이를 포함하는 마이코박테리아 감염증에 대한 백신 조성물
|
US11083788B2
(en)
|
2014-10-10 |
2021-08-10 |
The Regents Of The University Of Michigan |
Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease
|
AU2015252119A1
(en)
|
2014-11-07 |
2016-05-26 |
Takeda Vaccines, Inc. |
Hand, foot, and mouth vaccines and methods of manufacture and use thereof
|
AR102547A1
(es)
|
2014-11-07 |
2017-03-08 |
Takeda Vaccines Inc |
Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
|
WO2016141320A2
(fr)
|
2015-03-05 |
2016-09-09 |
Northwestern University |
Virus non neuro-invasifs et leurs utilisations
|
GB201518684D0
(en)
|
2015-10-21 |
2015-12-02 |
Glaxosmithkline Biolog Sa |
Vaccine
|
WO2017158426A1
(fr)
|
2016-03-14 |
2017-09-21 |
University Of Oslo |
Immunoglobulines génétiquement transformées ayant une liaison à fcrn altérée
|
WO2017158421A1
(fr)
|
2016-03-14 |
2017-09-21 |
University Of Oslo |
Immunoglobulines anti-virales synthétiques
|
WO2017201390A1
(fr)
|
2016-05-19 |
2017-11-23 |
The Regents Of The University Of Michigan |
Nouvelles compositions adjuvantes
|
EP3471761A2
(fr)
|
2016-06-21 |
2019-04-24 |
University Of Oslo |
Fragments de vaccin de liaison à hla et leurs utilisations
|
BR112019003462A2
(pt)
|
2016-08-23 |
2019-06-25 |
Glaxosmithkline Biologicals Sa |
proteína de fusão, polinucleotídeo, vetor viral, composição farmacêutica, uso de uma proteína de fusão, polinucleotídeo, vetor viral ou composição farmacêutica, e, método para tratar ou prevenir infecção de hepatite b viral ou infecção de hepatite c viral
|
EP3518966A1
(fr)
|
2016-09-29 |
2019-08-07 |
GlaxoSmithKline Biologicals S.A. |
Compositions et méthodes de traitement d'une infection par hpv persistante
|
WO2018096396A1
(fr)
|
2016-11-22 |
2018-05-31 |
University Of Oslo |
Variants d'albumine et leurs utilisations
|
GB201620968D0
(en)
|
2016-12-09 |
2017-01-25 |
Glaxosmithkline Biologicals Sa |
Adenovirus polynucleotides and polypeptides
|
WO2018231706A1
(fr)
|
2017-06-11 |
2018-12-20 |
Molecular Express, Inc. |
Méthodes et compositions destinées à des formulations vaccinales contre des troubles liés à une substance, et leurs utilisations
|
CA3067224A1
(fr)
|
2017-06-15 |
2018-12-20 |
Infectious Disease Research Institute |
Supports lipidiques nanostructures et emulsions stables et leurs utilisations
|
WO2019048936A1
(fr)
|
2017-09-07 |
2019-03-14 |
University Of Oslo |
Molécules vaccinales
|
JP2020533338A
(ja)
|
2017-09-07 |
2020-11-19 |
ユニバーシティ オブ オスロUniversity of Oslo |
ワクチン分子
|
BR112020008652A2
(pt)
|
2017-11-03 |
2020-11-10 |
Takeda Vaccines, Inc. |
vacinas e composições imunogênicas contra zika e métodos de uso das mesmas
|
GB201721069D0
(en)
|
2017-12-15 |
2018-01-31 |
Glaxosmithkline Biologicals Sa |
Hepatitis B Immunisation regimen and compositions
|
GB201721068D0
(en)
|
2017-12-15 |
2018-01-31 |
Glaxosmithkline Biologicals Sa |
Hepatitis B immunisation regimen and compositions
|
BR112020024285A2
(pt)
|
2018-06-12 |
2021-03-02 |
Glaxosmithkline Biologicals S.A. |
polinucleotídeos e polipeptídeos de adenovírus
|
WO2020030572A1
(fr)
|
2018-08-07 |
2020-02-13 |
Glaxosmithkline Biologicals Sa |
Processus et vaccins
|
EP3897846A1
(fr)
|
2018-12-21 |
2021-10-27 |
GlaxoSmithKline Biologicals SA |
Méthodes d'induction d'une réponse immunitaire
|
BR112021017584A2
(pt)
|
2019-03-05 |
2021-11-09 |
Glaxosmithkline Biologicals Sa |
Regime e composições de imunização contra hepatite b
|
CA3141577A1
(fr)
|
2019-05-25 |
2020-12-03 |
Infectious Disease Research Institute |
Composition et procede de sechage par atomisation d'une emulsion de vaccin et d'adjuvant
|
EP4103587A1
(fr)
|
2020-02-14 |
2022-12-21 |
Immunor AS |
Vaccin contre le coronavirus
|
WO2024052882A1
(fr)
|
2022-09-09 |
2024-03-14 |
Access To Advanced Health Institute |
Composition de vaccin immunogène incorporant une saponine
|